Contrasting Keros Therapeutics (NASDAQ:KROS) & CohBar (NASDAQ:CWBR)

CohBar (NASDAQ:CWBR) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares CohBar and Keros Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CohBar	N/A	N/A	-$12.18 million	N/A	N/A
Keros Therapeutics	$150,000.00	14,992.99	-$152.99 million	($5.13)	-11.68

CohBar has higher earnings, but lower revenue than Keros Therapeutics.

Profitability

This table compares CohBar and Keros Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CohBar	N/A	N/A	N/A
Keros Therapeutics	-62,012.55%	-44.73%	-41.06%

Analyst Ratings

This is a summary of current recommendations for CohBar and Keros Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CohBar	0	0	0	0	N/A
Keros Therapeutics	0	0	11	0	3.00

Keros Therapeutics has a consensus price target of $89.11, indicating a potential upside of 48.67%. Given Keros Therapeutics’ higher possible upside, analysts plainly believe Keros Therapeutics is more favorable than CohBar.

Insider and Institutional Ownership

2.5% of CohBar shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 6.5% of CohBar shares are held by company insiders. Comparatively, 22.9% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

CohBar has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.

About CohBar

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

About Keros Therapeutics

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.